Concluding thoughts on data presented at ESMO 2023, and innovations still needed for improved survival of NSCLC—provided by Patrick Forde, MBBCh.
This is a video synopsis/summary of a Post Conference Perspectives involving Patrick Forde, MBBCh.
Forde summarizes that significant advances have been made in non–small cell lung cancer (NSCLC), especially in the first-line setting for advanced disease and increasingly for early-stage disease with neoadjuvant immunotherapy. He notes further work is needed to improve outcomes for early-stage patients without a pathologic complete response to neoadjuvant therapy. Additional adjuvant targeted therapy trials are warranted in oncogene-driven NSCLC subtypes beyond EGFR and ALK.
In advanced NSCLC, numerous first-line options now exist, but second-line options remain very limited following first-line chemoimmunotherapy. Forde discusses the inconclusive TROPION-LUNG01 (NCT04656652) study in a novel postchemoimmunotherapy second-line setting. Clearly more work is needed in the second-line advanced setting.
In first-line EGFR-mutant advanced NSCLC, Forde notes the MARIPOSA trial (NCT04487080) showed improved progression-free survival with amivantamab-nazartinib vs osimertinib, but toxicity was increased, so more data are needed before practice changes. In contrast, the second-line MARIPOSA-2 trial (NCT04988295) supports adding amivantamab to chemotherapy vs chemotherapy alone post osimertinib, given the HR of 0.44 favoring the combination. However, toxicity requires monitoring with amivantamab-containing regimens.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Provisional CDC data show that US babies gained roughly a year in life expectancy in 2022; study findings indicate that the COVID-19 pandemic significantly raised the risk of preterm birth for expectant California mothers; New York Attorney General Letitia James said about 4 million New Yorkers were affected by a data breach of the medical transcription company Perry Johnson & Associates.
Read More
A Look at Racial Disparities in US HPV Vaccine Uptake
March 1st 2022On this episode of Managed Care Cast, Leslie Cofie, PhD, MPH, an assistant professor of health education and promotion at the College of Health and Human Performance, East Carolina University, discusses his work on identifying and addressing racial disparities in human papillomavirus (HPV) vaccine uptake in the United States.
Listen
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More